Oxysterol receptors and their therapeutic applications in cancer conditions

Expert Opinion on Therapeutic Targets

Volumn 17, Issue 9, 2013, Pages 1029-1038

  De Boussac, Hugues ^a,b,c   Alioui, Anthony ^a,b,c   Viennois, Emilie ^a,b,c,d   Dufour, Julie ^a,b,c   Trousson, Amalia ^a,b,c   Vega, Aurélie ^a,b,c   Guy, Laurent ^e   Volle, David H ^a,b,c   Lobaccaro, Jean Marc A ^a,b,c   Baron, Silvère ^a,b,c  

^a UNIVERSITÉ CLERMONT AUVERGNE   (France)

^b Faculté de Médecine   (France)

^c CRNH AUVERGNE   (France)

^d GEORGIA STATE UNIVERSITY   (United States)

^e SERVICE DE RHUMATOLOGIE   (France)

Author keywords

Cancer therapy; Cholesterol homeostasis; Liver X receptors; Oxysterols

Indexed keywords

BETA CATENIN; CASPASE 3; CHEMOKINE RECEPTOR CCR7; LIVER X RECEPTOR; OXYSTEROL; PROTEIN BAX;

APOPTOSIS; B LYMPHOCYTE; BREAST CANCER; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; COLORECTAL CANCER; DENDRITIC CELL; DISEASE ASSOCIATION; GALLBLADDER CANCER; GLIOBLASTOMA; NEOPLASM; OVARY CANCER; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; T LYMPHOCYTE; TUMOR IMMUNITY;

ANIMALS; CHOLESTEROL; HOMEOSTASIS; HUMANS; NEOPLASMS; ORPHAN NUCLEAR RECEPTORS;

EID: 84882649891     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2013.820708     Document Type: Review

References (100)

1. Bjorkhem I, Diczfalusy U. Oxysterols: friends, foes, or just fellow passengers? Arterioscler Thromb Vasc Biol 2002;22:734-42
2. Javitt NB. Oxysterols: novel biologic roles for the 21st century. Steroids 2008;73:149-57
3. Schroepfer GJ. Oxysterols: modulators of cholesterol metabolism and other processes. Physiol Rev 2000;80:361-554
4. Rooney MW, Yachnin S, Kucuk O, et al. Oxygenated cholesterols synergistically immobilize acyl chains and enhance protein helical structure in human erythrocyte membranes. Biochim Biophys Acta 1985;820:33-9
5. Kucuk O, Stoner-Picking J, Yachnin S, et al. Inhibition of NK cell-mediated cytotoxicity by oxysterols. Cell Immunol 1992;139:541-9
6. Vejux A, Guyot S, Montange T, et al. Phospholipidosis and down-regulation of the PI3-K/PDK-1/Akt signalling pathway are vitamin E inhibitable events associated with 7-ketocholesterol-induced apoptosis. J Nutr Biochem 2009;20:45-61
7. Moog C, Deloulme JC, Baudier J, et al. Membrane-related oxysterol function: preliminary results on the modification of protein kinase C activity and substrate phosphorylation by 7 beta, 25-dihydroxycholesterol. Biochimie 1991;73:1321-6
8. Duran MJ, Pierre SV, Lesnik P, et al. 7-ketocholesterol inhibits Na, K-ATPase activity by decreasing expression of its a1-subunit and membrane fluidity in human endothelial cells. Cell Mol Biol (Noisy-le-grand) 2010;56(Suppl): OL1434-41
9. Ragot K, Mackrill JJ, Zarrouk A, et al. Absence of correlation between oxysterol accumulation in lipid raft microdomains, calcium increase, and apoptosis induction on 158N murine oligodendrocytes. Biochem Pharmacol 2013;doi:10.1016/j.bcp.2013.02.028
10. Goldstein JL, DeBose-Boyd RA, Brown MS. Protein sensors for membrane sterols. Cell 2006;124:35-46
11. Janowski BA, Shan B, Russell DW. The hypocholesterolemic agent LY295427 reverses suppression of sterol regulatory element-binding protein processing mediated by oxysterols. J Biol Chem 2001;276:45408-16
12. Mark M, Muller P, Maier R, et al. Effects of a novel 2, 3-oxidosqualene cyclase inhibitor on the regulation of cholesterol biosynthesis in HepG2 cells. J Lipid Res 1996;37:148-58
13. Corcoran RB, Scott MP. Oxysterols stimulate Sonic hedgehog signal transduction and proliferation of medulloblastoma cells. Proc Natl Acad Sci USA 2006;103:8408-13
14. Dwyer JR, Sever N, Carlson M, et al. Oxysterols are novel activators of the hedgehog signaling pathway in pluripotent mesenchymal cells. J Biol Chem 2007;282:8959-68
15. Jeong J, McMahon AP. Cholesterol modification of Hedgehog family proteins. J Clin Invest 2002;110:591-6
16. Infante RE, Abi-Mosleh L, Radhakrishnan A, et al. Purified NPC1 protein. I. Binding of cholesterol and oxysterols to a 1278-amino acid membrane protein. J Biol Chem 2008;283:1052-63
17. Infante RE, Radhakrishnan A, Abi-Mosleh L, et al. Purified NPC1 protein: II. Localization of sterol binding to a 240-amino acid soluble luminal loop. J Biol Chem 2008;283:1064-7518.
18. Yan D, Olkkonen VM. Characteristics of oxysterol binding proteins. Int Rev Cytol 2008;265:253-85
19. Wang Y, Kumar N, Crumbley C, et al. A second class of nuclear receptors for oxysterols: regulation of RORalpha and RORgamma activity by 24S-hydroxycholesterol (cerebrosterol). Biochim Biophys Acta 2010;1801:917-23
20. Wada T, Kang HS, Jetten AM, et al. The emerging role of nuclear receptor RORalpha and its crosstalk with LXR in xeno-and endobiotic gene regulation. Exp Biol Med (Maywood) 2008;233:1191-201
21. Deng R, Yang D, Yang J, et al. Oxysterol 22(R)-hydroxycholesterol induces the expression of the bile salt export pump through nuclear receptor farsenoid X receptor but not liver X receptor. J Pharmacol Exp Ther 2006;317:317-25
22. Shenoy SD, Spencer TA, Mercer-Haines NA, et al. CYP3A induction by liver x receptor ligands in primary cultured rat and mouse hepatocytes is mediated by the pregnane X receptor. Drug Metab Dispos 2004;32:66-71
23. Langmade SJ, Gale SE, Frolov A, et al. Pregnane X receptor (PXR) activation: a mechanism for neuroprotection in a mouse model of Niemann-Pick C disease. Proc Natl Acad Sci USA 2006;103:13807-12
24. Trousson A, Bernard S, Petit PX, et al. 25-hydroxycholesterol provokes oligodendrocyte cell line apoptosis and stimulates the secreted phospholipase A2 type IIA via LXR beta and PXR. J Neurochem 2009;109:945-58
25. Umetani M, Domoto H, Gormley AK, et al. 27-Hydroxycholesterol is an endogenous SERM that inhibits the cardiovascular effects of estrogen. Nat Med 2007;13:1185-92
26. DuSell CD, Umetani M, Shaul PW, et al. 27-hydroxycholesterol is an endogenous selective estrogen receptor modulator. Mol Endocrinol 2008;22:65-77
27. Janowski BA, Willy PJ, Devi TR, et al. An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature 1996;383:728-31
28. Lehmann JM, Kliewer SA, Moore LB, et al. Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. J Biol Chem 1997;272:3137-40
29. Janowski BA, Grogan MJ, Jones SA, et al. Structural requirements of ligands for the oxysterol liver X receptors LXRalpha and LXRbeta. Proc Natl Acad Sci USA 1999;96:266-71
30. Viennois E, Pommier AJ, Mouzat K, et al. Targeting liver X receptors in human health: deadlock or promising trail? Expert Opin Ther Targets 2011;15:219-32
31. Repa JJ, Mangelsdorf DJ. The role of orphan nuclear receptors in the regulation of cholesterol homeostasis. Annu Rev Cell Dev Biol 2000;16:459-81
32. Peet DJ, Turley SD, Ma W, et al. Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha. Cell 1998;93:693-704
33. Repa JJ, Turley SD, Lobaccaro JA, et al. Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science 2000;289:1524-9
34. Schultz JR, Tu H, Luk A, et al. Role of LXRs in control of lipogenesis. Genes Dev 2000;14:2831-8
35. Collins JL, Fivush AM, Watson MA, et al. Identification of a nonsteroidal liver X receptor agonist through parallel array synthesis of tertiary amines. J Med Chem 2002;45:1963-6
36. Repa JJ, Liang G, Ou J, et al. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes Dev 2000;14:2819-30
37. Venkateswaran A, Laffitte BA, Joseph SB, et al. Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha. Proc Natl Acad Sci USA 2000;97:12097-102
38. Venkateswaran A, Repa JJ, Lobaccaro JM, et al. Human white/murine ABC8 mRNA levels are highly induced in lipid-loaded macrophages. A transcriptional role for specific oxysterols. J Biol Chem 2000;275:14700-7
39. Wu JE, Basso F, Shamburek RD, et al. Hepatic ABCG5 and ABCG8 overexpression increases hepatobiliary sterol transport but does not alter aortic atherosclerosis in transgenic mice. J Biol Chem 2004;279:22913-25
40. Yu L, York J, Von Bergmann K, et al. Stimulation of cholesterol excretion by the liver X receptor agonist requires ATP-binding cassette transporters G5 and G8. J Biol Chem 2003;278:15565-70
41. Repa JJ, Berge KE, Pomajzl C, et al. Regulation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors alpha and beta. J Biol Chem 2002;277:18793-800
42. Zelcer N, Hong C, Boyadjian R, et al. LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor. Science 2009;325:100-4
43. Cummins CL, Volle DH, Zhang Y, et al. Liver X receptors regulate adrenal cholesterol balance. J Clin Invest 2006;116:1902-12
44. Volle DH, Mouzat K, Duggavathi R, et al. Multiple roles of the nuclear receptors for oxysterols liver X receptor to maintain male fertility. Mol Endocrinol 2007;21:1014-27
45. Lee JH, Gong H, Khadem S, et al. Androgen deprivation by activating the liver X receptor. Endocrinology 2008;149:3778-88
46. Laffitte BA, Chao LC, Li J, et al. Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue. Proc Natl Acad Sci USA 2003;100:5419-24
47. Dalen KT, Ulven SM, et al. Expression of the insulin-responsive glucose transporter GLUT4 in adipocytes is dependent on liver X receptor alpha. J Biol Chem 2003;278:48283-91
48. Cha JY, Repa JJ. The liver X receptor (LXR) and hepatic lipogenesis. The carbohydrate-response element-binding protein is a target gene of LXR. J Biol Chem 2007;282:743-51
49. Joseph SB, Castrillo A, Laffitte BA, et al. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat Med 2003;9:213-19
50. Castrillo A, Joseph SB, Vaidya SA, et al. Crosstalk between LXR and toll-like receptor signaling mediates bacterial and viral antagonism of cholesterol metabolism. Mol Cell 2003;12:805-1651.
51. Chuu C-P, Lin H-P. Antiproliferative effect of LXR agonists T0901317 and 22 (R)-hydroxycholesterol on multiple human cancer cell lines. Anticancer Res 2010;30:3643-8
52. Mehrotra A, Kaul D, Joshi K. LXR-A selectively reprogrammes cancer cells to enter into apoptosis. Mol Cell Biochem 2011;349:41-55
53. Dufour J, Pommier A, Alves G, et al. Lack of liver x receptors leads to cell proliferation in a model of mouse dorsal prostate epithelial cell. PLoS One 2013;8:e58876
54. Noghero A, Perino A, Seano G, et al. Liver X receptor activation reduces angiogenesis by impairing lipid raft localization and signaling of vascular endothelial growth factor receptor-2. Arterioscler Thromb Vasc Biol 2012;32:2280-8
55. Farwell WR, Scranton RE, Lawler EV, et al. The association between statins and cancer incidence in a veterans population. J Natl Cancer Inst 2008;100:134-9
56. Uno S, Endo K, Jeong Y, et al. Suppression of beta-catenin signaling by liver X receptor ligands. Biochem Pharmacol 2009;77:186-95
57. Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 2004;20:781-810
58. Vedin L-L, Gustafsson J-A, Steffensen KR. The oxysterol receptors LXRa and LXRb suppress proliferation in the colon. Mol Carcinog 2012;doi:10.1002/mc. 21924
59. Lo Sasso GL, Bovenga F, Murzilli S, et al.Liver X. Receptors Inhibit Proliferation of Human Colorectal Cancer Cells and Growth of Intestinal Tumors in Mice. Gastroenterology 2013;doi:10.1053/j.gastro.2013.02.00560.
60. Elmore RG, Ioffe Y, Scoles DR, et al. Impact of statin therapy on survival in epithelial ovarian cancer. Gynecol Oncol 2008;111:102-5
61. Scoles DR, Xu X, Wang H, et al. Liver X receptor agonist inhibits proliferation of ovarian carcinoma cells stimulated by oxidized low density lipoprotein. Gynecol Oncol 2010;116:109-16
62. Rough JJ, Monroy MA, Yerrum S, et al. Anti-proliferative effect of LXR agonist T0901317 in ovarian carcinoma cells. J Ovarian Res 2010;3:13
63. Alberts DS, Hallum AV III, Stratton-Custis M, et al. Phase I pharmacokinetic trial and correlative in vitro phase II tumor kinetic study of Apomine (SR-45023A), a novel oral biphosphonate anticancer drug. Clin Cancer Res 2001;7:1246-50
64. Miller DH, Fischer AK, Chu KF, et al. T0901317 inhibits cisplatin-induced apoptosis in ovarian cancer cells [corrected]. Int J Gynecol Cancer 2011;21:1350-6
65. Dale KM, Coleman CI, Henyan NN, et al. Statins and cancer risk: a meta-analysis. JAMA 2006;295:74-80
66. Vigushin DM, Dong Y, Inman L, et al. The nuclear oxysterol receptor LXRalpha is expressed in the normal human breast and in breast cancer. Med Oncol 2004;21:123-31
67. Fukuchi J, Kokontis JM, Hiipakka RA, et al. Antiproliferative effect of liver X receptor agonists on LNCaP human prostate cancer cells. Cancer Res 2004;64:7686-968.
68. El Roz A, Bard J-M, Huvelin J-M, et al. LXR agonists and ABCG1-dependent cholesterol efflux in MCF-7 breast cancer cells: relation to proliferation and apoptosis. Anticancer Res 2012;32:3007-13
69. Vedin L-L, Lewandowski SA, Parini P, et al. The oxysterol receptor LXR inhibits proliferation of human breast cancer cells. Carcinogenesis 2009;30:575-9
70. Gong H, Guo P, Zhai Y, et al. Estrogen deprivation and inhibition of breast cancer growth in vivo through activation of the orphan nuclear receptor liver X receptor. Mol Endocrinol 2007;21:1781-90
71. Lazcano-Ponce EC, Miquel JF, Munoz N, et al. Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin 2001;51:349-64
72. Gabbi C, Kim H-J, Barros R, et al. Estrogen-dependent gallbladder carcinogenesis in LXRbeta-/-female mice. Proc Natl Acad Sci USA 2010;107:14763-873.
73. De Boussac H, Pommier AJ, Dufour J, et al. LXR, prostate cancer and cholesterol: the Good, the Bad and the Ugly. Am J Cancer Res 2013;3:58-69
74. Fukuchi J, Hiipakka RA, Kokontis JM, et al. Androgenic suppression of ATP-binding cassette transporter A1 expression in LNCaP human prostate cancer cells. Cancer Res 2004;64:7682-5
75. Chuu CP, Hiipakka RA, Kokontis JM, et al. Inhibition of tumor growth and progression of LNCaP prostate cancer cells in athymic mice by androgen and liver X receptor agonist. Cancer Res 2006;66:6482-6
76. Viennois E, Esposito T, Dufour J, et al. Lxra regulates the androgen response in prostate epithelium. Endocrinology 2012;153:3211-23
77. Pommier AJ, Alves G, Viennois E, et al. Liver X Receptor activation downregulates AKT survival signaling in lipid rafts and induces apoptosis of prostate cancer cells. Oncogene 2010;29:2712-23
78. Dufour J, Viennois E, De Boussac H, et al. Oxysterol receptors, AKT and prostate cancer. Curr Opin Pharmacol 2012;12:724-8
79. Pommier AJC, Dufour J, Alves G, et al. Liver x receptors protect from development of prostatic intra-epithelial neoplasia in mice. PLoS Genet 2013;9:e100348380.
80. Guo D, Reinitz F, Youssef M, et al. An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent81. Moschetta A. Nuclear receptor LXR as a novel therapeutic antitumoral target inglioblastoma. Cancer Discov 2011;1:381-2
81. Geyeregger R, Shehata M, Zeyda M, et al. Liver X receptors interfere with cytokine-induced proliferation and cell survival in normal and leukemic lymphocytes. J Leukoc Biol 2009;86:1039-48
82. Villablanca EJ, Raccosta L, Zhou D, et al. Tumor-mediated liver X receptor-alpha activation inhibits CC chemokine receptor-7 expression on dendritic cells and dampens antitumor responses. Nat Med 2010;16:98-10584.
83. Viennois E, Mouzat K, Dufour J, et al. Selective liver X receptor modulators (SLiMs): what use in human health? Mol Cell Endocrinol 2012;351:129-41
84. DiBlasio-Smith EA, Arai M, Quinet EM, et al. Discovery and implementation of transcriptional biomarkers of synthetic LXR agonists in peripheral blood cells. J Transl Med 2008;6:59
85. Katz A, Udata C, Ott E, et al. Safety, pharmacokinetics, and pharmacodynamics of single doses of LXR-623, a novel liver X-receptor agonist, in healthy participants. J Clin Pharmacol 2009;49:643-987.
86. Kaneko E, Matsuda M, Yamada Y, et al. Induction of intestinal ATP-binding cassette transporters by a phytosterol-derived liver X receptor agonist. J Biol Chem 2003;278:36091-8
87. Yasuda T, Grillot D, Billheimer JT, et al. Tissue-specific liver X receptor activation promotes macrophage reverse cholesterol transport in vivo. Arterioscler Thromb Vasc Biol 2010;30:781-6
88. Weinhofer I, Kunze M, Rampler H, et al. Liver X receptor alpha interferes with SREBP1c-mediated Abcd2 expression. Novel cross-talk in gene regulation. J Biol Chem 2005;280:41243-51
89. Sun Y, Yao J, Kim T-W, et al. Expression of liver X receptor target genes decreases cellular amyloid beta peptide secretion. J Biol Chem 2003;278:27688-94
90. Koldamova RP, Lefterov IM, Staufenbiel M, et al. The liver X receptor ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer's disease. J Biol Chem 2005;280:4079-88
91. Zelcer N, Khanlou N, Clare R, et al. Attenuation of neuroinflammation and Alzheimer's disease pathology by liver x receptors. Proc Natl Acad Sci USA 2007;104:10601-6
92. Leoni V, Caccia C. Oxysterols as biomarkers in neurodegenerative diseases. Chem Phys Lipids 2011;164:515-24
93. Wang L, Schuster GU, Hultenby K, et al. Liver X receptors in the central nervous system: from lipid homeostasis to neuronal degeneration. Proc Natl Acad Sci USA 2002;99:13878-83
94. Makoukji J, Shackleford G, Meffre D, et al. Interplay between LXR and Wnt/bcatenin signaling in the negative regulation of peripheral myelin genes by oxysterols. J Neurosci 2011;31:9620-9
95. Volle DH, Lobaccaro JM. Role of the nuclear receptors for oxysterols LXRs in steroidogenic tissues: beyond the 'foie gras', the steroids and sex? Mol Cell Endocrinol 2007;265-266:183-9
96. Mouzat K, Volat F, Baron S, et al. Absence of nuclear receptors for oxysterols liver X receptor induces ovarian hyperstimulation syndrome in mice. Endocrinology 2009;150:3369-75
97. Kosuri S, Akhtar NH, Smith M, et al. Review of salvage therapy for biochemically recurrent prostate cancer: the role of imaging and rationale for systemic salvage targeted anti-prostate-specific membrane antigen radioimmunotherapy. Adv Urol 2012;2012:921674
98. Tai W, Mahato R, Cheng K. The role of HER2 in cancer therapy and targeted drug delivery. J Control Release 2010;146:264-75
99. Chiu S-J, Ueno NT, Lee RJ. Tumor-targeted gene delivery via anti-HER2 antibody (trastuzumab, Herceptin) conjugated polyethylenimine. J Control Release 2004;97:357-69
100. Park JW, Hong K, Kirpotin DB, et al. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res 2002;8:1172-81